The Framingham, Mass.-based implantable heart pump maker posted losses of -$27.4 million, or -$1.59 per share, on sales of $73.6 million for the 3 months ended June 30. That’s sales growth of 4.9% compared with Q2 2014, when HeartWare reported profits of $8.4 million.
Adjusted to exclude 1-time items, losses per share were -47¢, 2¢ ahead of the consensus estimate on Wall Street, where analysts were looking for sales of $71.9 million.
“We are pleased to report another quarter of solid financial results and achievement of record revenue and units sold during the 2nd quarter, with particular strength in the U.S. market,” president & CEO Doug Godshall said in prepared remarks. “In addition to this strong financial performance, we were pleased to have recently begun patient enrollment in our MVAD system CE Mark trial, a significant accomplishment for the company and an important step forward for this innovative, new device.”
The news sent HTWR shares up 7.4% to $88.44 apiece today in mid-day trading.